Immunomodulation and Immune Thrombocytopenia: Some Unmet Needs, Questions and Outlook

During the last 2 decades, new therapeutic strategies have been developed, particularly anti-CD20 agents and thrombopoietin-receptor (TPO-r) mimetics, for immune thrombocytopenia (ITP). However, although the new efficient drugs have deeply modified the therapeutic strategy and the disease prognosis, there are still unmet needs and challenges. Concerning rituximab, reassuring data concerning its safety has recently been reported. The main limitation of the treatment is its modest long-term efficacy, with frequent disease relapse.
Source: Seminars in Hematology - Category: Hematology Authors: Tags: April 2016 Suppl 1 ICIS Source Type: research